论文部分内容阅读
目的探讨非小细胞肺癌(NSCLC)组织中上皮钙黏蛋白(Ecadherin)的表达及与预后的关系。方法用组织阵列仪构建365例NSCLC患者手术切除癌组织标本的组织芯片,对该芯片进行Ecadherin免疫组化染色,并分析Ecadherin表达与临床病理资料及生存预后的关系。365例中,鳞癌116例、腺癌199例、腺鳞癌等组织类型50例。结果Ecadherin蛋白主要在肿瘤细胞的胞膜和细胞质中表达,有32.1%(117/365)为Ecadherin低表达。Ecadherin低表达与淋巴结转移(χ2=16.430,P=0.001)、肿瘤细胞低分化(χ2=9.243,P=0.010)以及临床病理分期(χ2=9.421,P=0.024)呈正相关,而与病理类型无明显关系;Ecadherin表达与NSCLC预后差密切相关(P<0.0001)。多因素生存分析表明,Ecadherin表达是NSCLC预后差的独立预后因素(P<0.001)。结论Ecadherin可能与NSCLC的进展有关,其表达状态是NSCLC独立预后因素。
Objective To investigate the expression of Ecadherin in non-small cell lung cancer (NSCLC) and its relationship with prognosis. Methods Tissue microarray specimens of 365 patients with NSCLC were excised by tissue array. Ecadherin immunohistochemical staining was performed on this chip. The relationship between Ecadherin expression and clinicopathological parameters and survival prognosis was analyzed. In 365 cases, there were 116 cases of squamous cell carcinoma, 199 cases of adenocarcinoma and 50 cases of adenoid squamous cell carcinoma. Results Ecadherin protein was mainly expressed in the cell membrane and cytoplasm of tumor cells, with a low expression of Ecadherin in 32.1% (117/365). Low expression of Ecadherin was positively correlated with lymph node metastasis (χ2 = 16.430, P = 0.001), poorly differentiated tumor cells (χ2 = 9.243, P = 0.010) and clinicopathologic stage (χ2 = 9.421, P = 0.024) Significant relationship; Ecadherin expression and prognosis of NSCLC closely related (P <0.0001). Multivariate survival analysis showed that Ecadherin expression was an independent predictor of poor prognosis in NSCLC (P <0.001). Conclusion Ecadherin may be related to the progression of NSCLC, and its expression status is an independent prognostic factor of NSCLC.